GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Other Financing

Astellas Pharma (STU:YPH) Other Financing : €-108 Mil (TTM As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Astellas Pharma Other Financing?

Astellas Pharma's Other Financing for the three months ended in Sep. 2024 was €-3 Mil.

Astellas Pharma's Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 was €-108 Mil.

Astellas Pharma Other Financing Historical Data

The historical data trend for Astellas Pharma's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Other Financing Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.12 -17.53 -19.37 -22.48 -101.56

Astellas Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.84 -24.13 -54.63 -26.25 -2.57

Astellas Pharma Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-108 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Other Financing Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Other Financing
Comparable Companies
TSE:4578 TSE:4151 TSE:4528 TSE:4536 TSE:4552 TSE:4882 TSE:4568 TSE:4519 LLY JNJ MRK ABBV XSWX:ROG LSE:AZN XSWX:NOVN PFE AMGN XPAR:SAN BMY GILD
Traded in Other Exchanges
ALPMY:USA ALPMF:USA 4503:Japan YPH:Germany
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Website
http://www.astellas.com
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines